Form 4: Cyclacel Director Boosts Common Stock Holdings

Cyclacel Pharmaceuticals Director and 10% owner, Ong Yee Lung, exchanged Series C Common Stock Warrants for 186,465 shares of common stock.

Summary

• Ong Yee Lung, a Director and 10% Owner of Cyclacel Pharmaceuticals, Inc. (CYCC), exchanged 186,465 Series C Common Stock Purchase Warrants for an equal number of Common Stock shares.
• The transaction occurred on September 4, 2025, pursuant to a warrant exchange agreement.
• Following the transaction, Ong Yee Lung beneficially owns 404,465 shares of Common Stock directly.
• The Series C Common Stock Warrants had an exercise price of $10.2 and an expiration date of June 20, 2030.
• After the exchange, Ong Yee Lung retains 31,535 derivative securities (warrants).

Sentiment

Score: 7

Explanation: The exchange of warrants for common stock by a director and 10% owner indicates increased direct equity exposure and alignment of interests, which is generally viewed favorably by the market.

Positives

• Increased direct ownership of common stock by a significant insider (Director and 10% Owner), Ong Yee Lung, through the exchange of warrants.
• The transaction demonstrates a conversion of potential future equity into current direct equity, aligning insider interests with shareholders.

Future Outlook

No forward-looking statements are provided.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context.

Related Party Transactions

• The warrant exchange between the company and its director/10% owner, Ong Yee Lung, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May view the increased direct ownership by a significant insider as a positive signal of confidence in the company's future.

Key Dates

Recommendation

The transaction, involving a significant insider increasing their direct equity stake, is a positive signal. However, a single Form 4 filing typically doesn't warrant a 'buy' or 'sell' recommendation without broader financial context. It reinforces a 'hold' position for existing investors and provides a positive data point for potential investors.

Keywords

Cyclacel Pharmaceuticals, CYCC, Form 4, insider transaction, beneficial ownership, warrant exchange, common stock, director, 10% owner, Ong Yee Lung